Intraocular inflammation following intravitreal injections of anti-vascular endothelial growth factor drugs
NI-IOI represents an emergent treatment-related adverse event, that can be reversible when adequately managed, contrasting with the sight-threatening severe cases of IE. We emphasize the importance of maintaining active surveillance in patients under intravitreal therapy.
Authors
- Ângela Carneiro (ORCID: https://orcid.org/0000-0002-3370-7243)
- Adélia Mendes (ORCID: https://orcid.org/0000-0001-6636-0453)
- Ana Catarina Pedrosa (ORCID: https://orcid.org/0000-0001-6831-5488)
- Ana Margarida Ferreira (ORCID: https://orcid.org/0009-0000-3592-2820)
- Sónia Torres-Costa (ORCID: https://orcid.org/0000-0002-7079-9554)
- Carolina Maia (ORCID: https://orcid.org/0000-0002-5873-9196)
- Manuel Falcão (ORCID: https://orcid.org/0000-0003-4718-0910)
- Susana Costa Penas (ORCID: https://orcid.org/0000-0001-7696-1957)
- João Beato (ORCID: https://orcid.org/0000-0003-3820-4597)
- Cláudia Oliveira Ferreira
Institutions
- Universidade do Porto (PT)
- Hospital de São João (PT)
Publication Details
- Journal
- Graefe s Archive for Clinical and Experimental Ophthalmology
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1007/s00417-025-06875-w
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.00